April 11, 2008
Provectus Aims to Achieve Profit by 2010, Chief Says
Kelly Riddell of Bloomberg News interviews Provectus CEO Craig Dees, Ph.D. A copy of the
article is available here.
January 31, 2008
Knobias Reports on Importance of PH-10 Patent Allowance in India
Today's Knobias smallcap ClipReport features article on the importance of the recently received allowance
in India of a patent covering Provectus lead dermatology agent PH-10. A copy of the article is
available here.
January 31, 2008
Melanoma Clinical Trial Update
Genetic Engineering & Biotechnology News article gives update on Provectus phase 2 clinical trial of PV-10
for metastatic melanoma. A copy of the article is
available here.
December 13, 2007
Small Business Offers Big Advancements in Creating Cancer Drugs
A November 22, 2007 article in the business section of the Knoxville News Sentinel
highlights Provectus' innovative cancer treatment. A copy of the article is
available here.
November 23, 2007
Craig Dees, Ph.D. Comments On Anti-bacterial Wipes
A November 23rd entry in the Care-Mates(TM) Infection Protection blog
quotes Provectus CEO Craig Dees on the use of anti-bacterial soaps and wipes in the home
to help prevent infections.
The entire blog entry is available here.
November 15, 2007
Craig Dees, Ph.D. Comments On Biotech Partnering
Provectus CEO Craig Dees, Ph.D. comments on biotech partnering in an interview
for a November/December PharmaVOICE articled titled "Basic Research".
Read an excerpt from the article here.
October 17, 2007
Recipient of Melanoma Drug in Development Celebrates Two Cancer-Free Years
Eighty-six-year-old Keith Hora, a stage III melanoma patient included in a Phase I clinical trial of PV-10 conducted by Dr. Peter Hersey,
a medical oncologist and professor at the University of Newcastle in Australia, celebrates two cancer-free years.
Read the complete article here.
September 18, 2007
Webcast of Provectus Presentation at AG Edwards Emerging Growth Conference
President Tim Scott and CFO Peter Culpepper will be presenting at the
AG Edwards' Second Annual Emerging Growth Conference on September 18.
The presentation will be webcast at
http://www.wsw.com/webcast/agedwards22/pvct.
August 1, 2007
WATE 6 News Airs Story on PV-10
WATE 6 News in Knoxville, TN aired a story on July 31, 2007 about Provectus clinical trial efforts
with PV-10 and includes comments by Provectus CEO Craig Dees, Ph.D.
A summary article and link to the video is available at here.
June 6, 2007
Craig Dees Comments on PV-10 in PharmaVOICE Article
In a June 2007 PharmaVOICE article titled "Harnessing the Power of the Immune System", Craig Dees, Ph.D
comments on PV-10 and engaging the immune system to combat cancer.
The article is available here.
April 29, 2008
Provectus Pharmaceuticals to Present at the Big Dog IV Small Cap Conference
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT,
http://www.pvct.com),
has announced that Provectus Chairman and CEO, Craig Dees, Ph.D. will present at the Big Dog IV Small Cap Conference being held at the Wynn Las Vegas on Friday, May 2nd, 2008 at 10:40 a.m. PDT.
Read the complete article here.
April 23, 2008
Provectus Pharmaceuticals Will Present at Inaugural LD MICRO Conference
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT,
http://www.pvct.com),
a development-stage oncology and dermatology biopharmaceutical company, has announced that it will present at LD MICRO's first annual conference at the Omni Los Angeles Hotel at 10:30 AM on April 29, 2008.
Read the complete article here.
April 15, 2008
Provectus Pharmaceuticals Receives Patent Allowance in the EU for PH-10 Dermatology Agent
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT,
http://www.pvct.com),
a development-stage oncology and dermatology biopharmaceutical company, has received allowance of its patent application in the European Union covering its lead dermatology agent, PH-10, along with a number of related agents and their use. Provectus has also received allowance of another patent application in Canada covering applicator devices used with PH-10 and related agents. The pending patents cover topical products for treatment of skin diseases such as psoriasis and eczema, along with certain medical devices for application of PH-10 to internal surfaces of the body.
Read the complete article here.
March 31, 2008
Provectus Pharmaceuticals Announces Financial Results for Year End 2007
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT,
http://www.pvct.com),
a development-stage oncology and dermatology biopharmaceutical company, has announced its financial results for the year ended December 31, 2007.
Read the complete article here.
March 4, 2008
Provectus Pharmaceuticals Receives US Patent Allowance to Provide Further Protection for Novel Photodynamic Drug PH-12
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT,
http://www.pvct.com),
a development-stage oncology and dermatology biopharmaceutical company, has received allowance of a second US patent application protecting a novel photoactive analog of its lead photodynamic product PH-10, from the United States Patent and Trademark Office (USPTO). The pending patent covers systemic use of the drug, PH-12, for photodynamic treatment of cancer, skin diseases, and other tissue disorders using visible light activation.
Read the complete article here.
February 26, 2008
Provectus Pharmaceuticals Receives Patent Allowances in Europe and China
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT,
http://www.pvct.com),
a development-stage oncology and dermatology biopharmaceutical company, has received allowance of its patent applications in Europe and China covering diagnostic use of PV-10 and a number of related agents in CT and MRI imaging. The pending patents cover products for diagnosis of cancer and other serious diseases.
Read the complete article here.
January 14, 2008
Provectus Pharmaceuticals Receives Patent Allowance in India
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT,
http://www.pvct.com),
a development-stage oncology and dermatology biopharmaceutical company, has received allowance of its patent application in India covering its lead dermatology agent, PH-10, along with a number of related agents. The pending patent covers topical products for treatment of skin diseases such as psoriasis and eczema. Additionally, a range of active compounds are protected, each related to the active ingredient in PH-10.
Read the complete article here.
January 9, 2008
Provectus Pharmaceuticals CEO Craig Dees, PhD Issues Executive Overview Letter
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Craig Dees, PhD, chief executive officer of Provectus Pharmaceuticals, Inc.
(OTCBB:
PVCT,
http://www.pvct.com),
has published his 2007 executive overview statement. The following letter from Dr. Dees was posted on the Company's website this morning. Additionally, management will present to institutions and retail brokers in Boston, Chicago, New York, and other cities throughout 2008 to increase investor awareness and visibility.
Read the complete article here.
December 18, 2007
Provectus Pharmaceuticals Adds Second Center to Phase 2 Clinical Trial of PV-10
KNOXVILLE, Tenn.--(BUSINESS WIRE)-- Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT,
http://www.pvct.com)
has begun recruitment for its Phase 2 clinical trial of the Company's lead oncology agent PV-10 at a second major center, now covering Brisbane, Australia in addition to Sydney, Australia. Over the next several months, the Company expects to continue expansion of the study to include sites in most major population centers in Australia as well as several sites in the United States.
Read the complete article here.
December 11, 2007
Provectus Pharmaceuticals Receives Patent in India for Lead Oncology Product
KNOXVILLE, Tenn.--(BUSINESS WIRE)-- Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT,
http://www.pvct.com)
has received a patent in India protecting its lead oncology agent, PV-10, along with a number of related agents.
Read the complete article here.
